RXRX

Recursion Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · recursion.com

$3.39

Mkt Cap $1.5B

52w Low $2.80 13.5% of range 52w High $7.18

50d MA $3.42 200d MA $4.55

P/E (TTM) -2.4x

EV/EBITDA -2.1x

P/B 1.3x

Debt/Equity 0.1x

ROE -57.0%

P/FCF -4.8x

RSI (14) —

ATR (14) —

Beta 1.01

50d MA $3.42

200d MA $4.55

Avg Volume 16.1M

About

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of ne…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 25, 2026	AMC	-0.28	-0.21	+25.0%	3.77	-2.4%	+0.0%	-2.7%	-3.7%	-6.1%	-3.4%	-22.0%	—
Nov 5, 2025	AMC	-0.38	-0.36	+5.3%	4.96	+0.4%	-6.9%	-6.9%	-9.1%	-5.0%	-6.2%	-5.0%	—
Aug 5, 2025	AMC	-0.35	-0.41	-17.1%	5.53	-2.0%	-0.9%	-2.2%	-3.1%	-4.3%	-2.2%	-18.3%	—
May 5, 2025	AMC	-0.44	-0.50	-13.6%	4.76	-2.1%	-12.6%	-12.0%	-7.8%	-9.0%	-2.5%	+3.2%	—
Feb 28, 2025	AMC	-0.44	-0.53	-20.5%	7.51	+4.8%	-12.3%	-13.8%	-12.4%	-16.9%	-12.3%	-29.6%	—
Nov 6, 2024	AMC	-0.33	-0.34	-3.0%	6.97	-0.7%	-0.6%	+1.9%	+12.5%	+8.8%	+5.0%	+14.9%	—
Aug 8, 2024	AMC	-0.35	-0.40	-14.3%	6.64	+2.9%	-5.3%	-9.2%	-1.5%	-5.4%	+0.8%	-7.8%	—
May 9, 2024	AMC	-0.43	-0.39	+9.3%	8.64	+4.7%	-0.5%	+9.7%	+16.3%	+15.9%	+10.1%	-0.2%	—
Feb 27, 2024	AMC	-0.46	-0.40	+13.0%	15.52	-10.8%	-16.6%	-13.3%	-17.5%	-20.7%	-23.3%	-35.8%	—
Nov 9, 2023	AMC	-0.38	-0.43	-13.2%	5.23	+1.1%	+4.4%	+11.5%	+23.5%	+37.3%	+27.5%	+44.6%	—
Aug 8, 2023	AMC	-0.38	-0.38	+0.0%	11.55	+0.4%	-5.0%	-13.6%	-17.1%	-19.3%	-20.4%	-27.6%	—
May 8, 2023	AMC	-0.34	-0.34	+0.0%	5.60	-1.1%	+2.9%	-1.6%	-3.6%	-5.5%	+0.0%	+62.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 30	JP Morgan	Maintains	Overweight → Overweight	—	$3.30	$3.33	+0.9%	+4.8%	+2.7%	—	—	—
Feb 26	BofA Securities	Maintains	Neutral → Neutral	—	$3.77	$3.68	-2.4%	+0.0%	-2.7%	-3.7%	-6.1%	-3.4%
Feb 26	Needham	Maintains	Buy → Buy	—	$3.77	$3.68	-2.4%	+0.0%	-2.7%	-3.7%	-6.1%	-3.4%
Dec 17	JP Morgan	Upgrade	Neutral → Overweight	—	$4.20	$4.51	+7.4%	+11.4%	+5.7%	+1.4%	+4.8%	+3.8%
Sep 11	Needham	Maintains	Buy → Buy	—	$4.54	$4.56	+0.4%	+6.8%	+6.4%	+5.1%	+6.6%	+3.7%
Jul 8	Needham	Maintains	Buy → Buy	—	$4.93	$5.01	+1.6%	+8.7%	+13.4%	+16.0%	+7.1%	+7.1%
Jun 16	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.92	$5.01	+1.8%	+1.6%	-1.6%	+3.9%	+2.2%	-1.8%
May 6	Needham	Maintains	Buy → Buy	—	$4.76	$4.66	-2.1%	-12.6%	-12.0%	-7.8%	-9.0%	-2.5%
Apr 10	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$4.65	$4.60	-1.1%	-3.0%	+23.9%	+18.5%	+21.3%	+14.4%
Apr 8	Needham	Maintains	Buy → Buy	—	$4.20	$4.49	+6.9%	-5.5%	+10.7%	+7.4%	+37.1%	+31.2%
Feb 28	Leerink Partners	Maintains	Market Perform → Market Perform	—	$7.67	$6.71	-12.5%	-2.1%	-14.1%	-15.6%	-14.2%	-18.6%
Feb 6	Needham	Maintains	Buy → Buy	—	$7.92	$8.14	+2.8%	-8.6%	-5.4%	-3.4%	-3.3%	+5.3%
Jan 8	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$7.49	$7.31	-2.4%	-3.1%	-8.1%	-10.0%	-15.6%	-14.3%
Dec 11	Needham	Maintains	Buy → Buy	—	$7.46	$7.89	+5.8%	+1.5%	-6.4%	-6.8%	-0.3%	-4.6%
Nov 20	Needham	Maintains	Buy → Buy	—	$6.27	$6.30	+0.5%	-3.7%	-8.3%	-9.1%	-4.3%	-6.1%
Nov 7	Needham	Maintains	Buy → Buy	—	$6.97	$6.92	-0.7%	-0.6%	+1.9%	+12.5%	+8.8%	+5.0%
Sep 4	Needham	Maintains	Buy → Buy	—	$6.07	$6.05	-0.3%	+0.5%	+1.6%	-2.5%	+0.8%	+4.1%
Sep 3	Leerink Partners	Maintains	Market Perform → Market Perform	—	$7.28	$6.46	-11.3%	-16.6%	-16.2%	-15.2%	-18.7%	-15.9%
Sep 3	Jefferies	Maintains	Hold → Hold	—	$7.28	$6.46	-11.3%	-16.6%	-16.2%	-15.2%	-18.7%	-15.9%
Aug 9	Needham	Maintains	Buy → Buy	—	$6.64	$6.83	+2.9%	-5.3%	-9.2%	-1.5%	-5.4%	+0.8%
Jul 11	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$7.23	$7.44	+2.9%	+6.2%	+15.6%	+13.4%	+18.9%	+15.5%
Jun 25	Needham	Maintains	Buy → Buy	—	$9.34	$9.45	+1.2%	+0.4%	-6.2%	-18.8%	-19.7%	-20.1%
May 10	Needham	Maintains	Buy → Buy	—	$8.64	$9.05	+4.7%	-0.5%	+9.7%	+16.3%	+15.9%	+10.1%
Apr 9	Needham	Maintains	Buy → Buy	—	$9.00	$9.00	+0.0%	+1.0%	-4.7%	-0.9%	-6.6%	-13.4%
Mar 4	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$12.81	$12.92	+0.9%	-4.0%	-7.0%	-11.6%	-13.0%	-12.6%
Feb 28	Needham	Maintains	Buy → Buy	—	$15.52	$13.84	-10.8%	-16.6%	-13.3%	-17.5%	-20.7%	-23.3%
Jan 17	Needham	Maintains	Buy → Buy	—	$10.76	$10.40	-3.3%	-4.6%	-8.1%	-10.5%	-2.6%	-1.1%
Jan 16	Needham	Maintains	Buy → Buy	—	$11.16	$10.93	-2.1%	-3.6%	-8.1%	-11.4%	-13.7%	-6.1%
Nov 13	JP Morgan	Maintains	Neutral → Neutral	—	$5.46	$5.36	-1.8%	+6.8%	+18.3%	+31.5%	+22.2%	+29.1%
Nov 9	Needham	Maintains	Buy → Buy	—	$5.63	$5.87	+4.3%	-7.1%	-3.0%	+3.6%	+14.7%	+27.5%
Sep 5	Needham	Maintains	Buy → Buy	—	$9.12	$9.07	-0.5%	-4.6%	-0.8%	-8.3%	-11.6%	-8.7%
Aug 9	Needham	Maintains	Buy → Buy	—	$11.55	$11.60	+0.4%	-5.0%	-13.6%	-17.1%	-19.3%	-20.4%
Jul 21	Needham	Maintains	Buy → Buy	—	$14.81	$15.30	+3.3%	+4.5%	-3.6%	-1.0%	-8.0%	-12.8%
Jul 18	Needham	Maintains	Buy → Buy	—	$13.40	$13.84	+3.2%	+1.7%	+18.3%	+10.5%	+15.4%	+6.5%
Jul 13	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$12.08	$11.98	-0.8%	+2.9%	-1.5%	+11.0%	+12.8%	+31.3%
Jul 13	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$12.08	$11.98	-0.8%	+2.9%	-1.5%	+11.0%	+12.8%	+31.3%
Jul 12	Needham	Maintains	Buy → Buy	—	$6.78	$14.67	+116.4%	+78.2%	+83.4%	+75.5%	+97.7%	+101.0%
Jul 12	Berenberg	Maintains	Buy → Buy	—	$6.78	$14.67	+116.4%	+78.2%	+83.4%	+75.5%	+97.7%	+101.0%
May 9	KeyBanc Capital Markets	Maintains	Overweight → Overweight	—	$5.60	$5.54	-1.1%	+2.9%	-1.6%	-3.6%	-5.5%	+0.0%
Jan 23	SVB Leerink	Maintains	Market Perform → Market Perform	—	$8.65	$8.55	-1.2%	+0.7%	-0.7%	-5.0%	-5.3%	-1.3%
Nov 9	Goldman Sachs	Maintains	Neutral → Neutral	—	$9.60	$9.76	+1.7%	+6.7%	+15.7%	+30.0%	+32.3%	+23.5%
Oct 25	SVB Leerink	Maintains	Market Perform → Market Perform	—	$10.91	$10.97	+0.6%	-1.7%	+0.4%	-2.9%	+1.6%	-3.3%
Aug 11	Goldman Sachs	Maintains	Neutral → Neutral	—	$9.87	$9.90	+0.3%	+13.6%	+22.0%	+31.3%	+24.8%	+16.7%
May 24	Goldman Sachs	Maintains	Neutral → Neutral	—	$5.80	$5.44	-6.1%	-6.0%	-5.3%	-1.4%	+6.4%	+5.5%
May 12	Goldman Sachs	Maintains	Neutral → Neutral	—	$5.04	$4.92	-2.4%	+3.4%	+11.9%	+12.5%	+21.2%	+11.5%
Apr 18	BofA Securities	Downgrade	Buy → Neutral	—	$7.46	$6.91	-7.4%	-12.5%	-13.1%	-13.8%	-17.7%	-19.6%
Mar 24	Goldman Sachs	Maintains	Neutral → Neutral	—	$6.91	$6.82	-1.3%	+0.4%	-2.2%	-0.6%	+5.9%	+3.2%
Mar 4	SVB Leerink	Downgrade	Outperform → Market Perform	—	$9.70	$9.22	-4.9%	-21.1%	-26.9%	-26.6%	-20.6%	-24.6%
Dec 8	SVB Leerink	Maintains	Outperform → Outperform	—	$20.72	$20.11	-3.0%	-4.4%	-9.1%	-8.4%	-6.2%	-10.1%
Aug 16	SVB Leerink	Maintains	Outperform → Outperform	—	$22.47	$22.73	+1.2%	-8.8%	-11.4%	-15.3%	-14.8%	-11.7%

Recent Filings

8-K · 5.02 !!! Very High

Recursion Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change

Recursion Pharmaceuticals appoints Christopher Gibson as director while he simultaneously declines re-election, suggesting a transitional leadership change with unclear long-term implications.

Apr 30

8-K · 5.02 !!! Very High

Unknown — 8-K 5.02: Executive Change

RXRX's chief financial officer departure effective April 6, 2026 creates near-term leadership uncertainty and potential operational disruption during what may be a critical business phase.

Mar 25

8-K · 7.01 ! Medium

Recursion Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure

Recursion Pharmaceuticals shared investor presentation materials from its February 25, 2026 earnings call, providing stakeholders updated company guidance and operational updates through publicly disclosed disclosure.

Feb 25

Data updated apr 26, 2026 11:49pm · Source: massive.com